

Differential induction of fusaric acid in the endophytic fungus, *Fusarium* sp. (UST-UVG10) by three different media results to enhanced, variable anti-staphylococcal and antimycobacterial activity

Hannah Joy C. Drapisa^{1,2}, Lloyd Christian Llamas^{1,2}, Elian Angelo Abellanosa¹, Warren S. Vidar³ and Allan Patrick G. Macabeo^{1*}

¹ Laboratory for Organic Reactivity, Discovery, and Synthesis (LORDS), Research Center for the Natural and Applied Sciences, University of Santo Tomas, España Blvd., Manila 1015, Philippines

² The Graduate School, University of Santo Tomas, España Blvd., Manila 1015, Philippines

³ Department of Chemistry & Biochemistry, University of North Carolina Greensboro, Greensboro, NC 27402, United States

* Corresponding author, E-mail: agmacabeo@ust.edu.ph

Abstract

The rise of drug-resistant pathogenic bacteria has enabled the discovery and innovative biotechnological production of antimicrobial substances. Among the widely used strategies to induce antimicrobial substances from fungi is the One Strain Many Compounds (OSMAC) approach where alteration of cultivation parameters are explored. Herein, we report a comparative study on the metabolic profile and antibacterial/antimycobacterial activity of the extracts obtained from the endophytic fungus *Fusarium* sp. (UST-UVG10) associated with the Philippine endemic Annonaceae plant *Uvaria valderramensis* using the OSMAC approach. *Fusarium* sp. (UST-UVG10) was fermented on three different media (Q6 ½, ZM ½, and YM 6.3) to obtain crude extracts for chemical profiling and antimicrobial activity assessments. Among the three extracts, only the ZM ½ extract exhibited strong inhibition against *Staphylococcus aureus* (ZOI = 13.85 mm). Evaluation of antituberculosis activity using the Microplate Alamar Blue Assay (MABA) showed the YM 6.3 extracts to exhibit inhibition against the fast-growing *Mycobacterium tuberculosis* H₃₇Rv (MIC = 62.0 µg/mL). Metabolic profiling using liquid chromatography-high resolution electrospray ionization mass spectrometry followed by dereplication with Global Natural Product Social Molecular Networking (GNPS) and SIRIUS databases illustrated induction of the mycotoxin picolinic acid derivative, fusaric acid in ZM ½ and the fungal antibiotic cyclodepsipeptide beauvericin in YM6.3 extracts. Fusaric acid was isolated, characterized, and exhibited profound antibacterial activity against *S. aureus* (MIC = 1.30 µg/mL) with moderate antimycobacterial activity against *M. tuberculosis* H₃₇Rv (MIC = 52.4 µg/mL). Overall, the present study demonstrated the correlative influence of culture medium components and the relative abundance of specific antimicrobial compounds, establishing a potential platform for targeted metabolite production.

Citation: Drapisa HJC, Llamas LC, Abellanosa EA, Vidar WS, Macabeo APG. 2024. Differential induction of fusaric acid in the endophytic fungus, *Fusarium* sp. (UST-UVG10) by three different media results to enhanced, variable anti-staphylococcal and antimycobacterial activity. *Studies in Fungi* 9: e007 <https://doi.org/10.48130/sif-0024-0007>

Introduction

The discovery and development of antibiotics are among the main accomplishments of the twentieth century. The prolonged, abusive use of antibiotics has fueled the emergence of drug-resistant pathogens, posing a grave threat to human health, with over 2 million challenging-to-treat infectious diseases annually, resulting in approximately 700,000 deaths^[1,2]. By 2050, it is projected that this mortality rate will soar to 10 million, underscoring the urgent need for the discovery of new secondary metabolites with potent, wide-ranging antibacterial properties in response to the rise of drug-resistant bacteria^[3].

Biotechnological approaches have been utilized in the production of antibiotics from natural product sources^[4] such as metabolomic engineering of *Streptomyces coelicolor* as a generic host for combinatorial biosynthesis and mutasynthesis in an effort to produce novel analogs of metabolites^[5]. Dereplication is an analytical methodology used for detecting known

compounds and is employed during the first step of antibiotic screening. This method resolves re-discovery problems, which makes use of mass spectrometry data and molecular network annotations based on public datasets such as the Global Natural Products Social (GNPS, <https://gnps.ucsd.edu>, accessed on 10 July 2023)^[6,7]. Other approaches include co-cultivation where two microorganisms are incubated in the same medium^[8]. Diversification of secondary metabolites cannot be achieved by mono cultivation, hence, the interaction between another microorganism in the culture medium can awaken silenced biosynthetic pathways to produce novel analogs^[9]. Exploring new habitats such as marine ecosystems^[10], taxa inhabiting extreme conditions^[11,12], difficult-to-reach habitats^[13], and plant-associated endophytes and epiphytes^[14] have been investigated.

Among the widely used methods to induce bioactive compounds from fungi is the One Strain Many Compounds (OSMAC) strategy. This method was first developed by Zeeck in the early 2000s and is notable for its simplicity and

practicality^[15]. OSMAC entails altering cultivation parameters such as medium composition and physical parameters (pH and temperature) or adding biosynthetic precursors and enzyme inhibitors/inducers to activate silent biosynthetic gene clusters and expand metabolite patterns produced by endophytes^[16]. One successful application of OSMAC in the induction of antimicrobial compounds in fungi are the production of the metabolites isopropylchaetominine, isoterrelumamide A, and 5'-epi-averufanin from the sponge-associated fungus *Aspergillus carneus* using three different culture media. Thus, it is an efficient approach in releasing nature's chemical diversity. Prior reports on the use of OSMAC illustrate coupling with mass spectrometry (MS) followed by dereplication for rapid identification of known secondary metabolites in crude extracts^[17–19]. Cryptic metabolites from marine-derived microorganisms are reportedly observed through dereplication when cultivated in different culture media, where epigenetic modifiers and different chemical components^[20] have been employed to awaken silent gene clusters.

With the increasing demand for antibiotic compounds that effectively kill rapidly evolving infectious pathogens, induction of antimicrobial compounds from fungi using OSMAC along with dereplication can provide an efficient approach to antibiotic drug discovery. In this paper, the induction of the antimicrobials fusaric acid and beauvericin from the endophytic fungus, *Fusarium* sp. (UST-UVG10) isolated from *Uvaria valderammensis* was investigated in three different media and resulted in differentiated antibacterial and antimycobacterial properties.

Materials and methods

Isolation of endophytic fungus

The fungal culture was previously isolated from healthy leaves of *Uvaria valderammensis*, collected in Valderrama, Antique, Panay Island, Philippines (11°00'05.60" N; 122°07'45.58" E) on April 2022. The plant parts were surface sterilized with 70% ethanol (1 min), 4% sodium hypochlorite (30 s), and sterile distilled water (SDW) (1 min) to remove any contaminants^[21]. The tissue imprint method was performed to confirm the efficacy of the surface sterilization protocol^[22]. The processed samples were then placed on a petri dish with potato dextrose agar (PDA) and incubated at 25 °C for a week until fungal colonies appeared. After isolation and purification, the endophytic fungi were grouped based on their colony appearance. After which, because of frequent occurrence and based on colony morphotype, the endophytic fungus assigned hitherto as UST-UVG10 was chosen for this study. The culture was duplicated and stored for long-term preservation in 50% aqueous glycerol solution at 4 °C.

Morphological characterization

Morphological characterizations were carried out for 14 d in the PDA plate, which involved observation of the fungal colony characteristics such as color, elevation, and margin, as well as some important microscopic features, including fungal spores' size and shape. These observations were made using the Euromex Nexius Zoom Stereo Microscope (S/N- EU 1980535) at magnifications of 1.5× to 10× and an Olympus CX23 binocular compound microscope. The fungal strain was assigned with accession number CMS903.23 by the UST-CMS.

Molecular analysis

The endophytic fungus UST-UVG10 was sent to MacroGen Inc., South Korea, for DNA extraction, purification, amplification, and gene sequencing. The amplification step was performed using the universal primers ITS1 (5'-TCCGTAGGTGAACCTGCGG-3') and ITS4 (5'-TCCTCCGCTTATTGATATGC-3'), as described in previous studies^[23]. The obtained sequence was subjected to BLAST search analysis to determine the highest percentage identity. Parameters for BLAST search were modified to include sequences from type materials and exclude uncultured specimens. Gathered sequences were analyzed using MEGA v. 11 using the Jukes-Cantor model with Gamma distribution (G+1) model of nucleotide substitution with 1,000 rapid bootstrap replicates. The phylogenetic tree was viewed using FigTree 1.4.0 and edited by Microsoft Office PowerPoint 365. The sequences used for analyses with accession numbers are given in Table 1.

Small scale fermentation and extraction

The pure fungal strain was inoculated in a 250 mL Erlenmeyer flask containing either 100 mL of Q6 ½ medium (D-glucose 0.25%, glycerine 1%, cottonseed flour 0.5%, demineralized water, pH 7.2), YM 6.3 medium (yeast extract 0.4%, malt extract 1%, glucose 0.4%, demineralized water, pH 6.3), or ZM ½ (molasses 0.5%, oat flour 0.5%, sucrose 0.4%, mannitol 0.4%, glucose 0.15%, calcium carbonate 0.15%, edamine 0.05%, ammonium sulfate 0.05%, demineralized water, pH 7.2). For this purpose, one-week-old cultures of *Fusarium* sp. (UST-UVG10) isolated on PDA were cut into small block pieces and

Table 1. Reference taxa used in this study with their strain number and GenBank accession numbers.

Taxa	Strain no.	GenBank accession numbers (ITS)	Ref.
<i>Fusarium dlamini</i>	NRRL 13164 ^T	NR 182425	[24]
<i>Fusarium dlamini</i>	NRRL 13164	U34572	[25]
<i>Fusarium acutatum</i>	NRRL 13308	U34573	[25]
<i>Fusarium acutatum</i>	CBS 402.97	MH862652	[26]
<i>Fusarium acutatum</i>	CBS 739.97	MH862669	[26]
<i>Fusarium acutatum</i>	CBS 402.97 ^T	NR_111142	[27]
<i>Fusarium phyllophilum</i>	NRRL 13617 ^T	NR_182426	[25]
<i>Fusarium phyllophilum</i>	NRRL 13617	U34574	[25]
<i>Fusarium hostae</i>	NRRL 29888 ^T	NR 171109	[28]
<i>Fusarium fujikuroi</i>	CBS 221.76	AB725607	[29]
<i>Fusarium fujikuroi</i>	CBS 221.76 ^T	NR_111889	[27]
<i>Fusarium fujikuroi</i>	CBS 221.76	MW827608	[30]
<i>Fusarium hechiense</i>	LC13644 ^T	NR_182846	[31]
<i>Fusarium hechiense</i>	LC13644	MW016454	[31]
<i>Fusarium elaeagni</i>	LC13627 ^T	NR_182845	[31]
<i>Fusarium elaeagni</i>	LC13627	MW016426	[31]
<i>Fusarium</i> sp.	NRRL28852	AF158304	[32]
<i>Fusarium</i> sp.	NRRL26793	AF158312	[32]
<i>Fusarium nygamai</i>	CBS 749.97	MH862671	[26]
<i>Fusarium nygamai</i>	NRRL 13448 ^T	NR 130698	[25]
<i>Fusarium nygamai</i>	CBS 749.97	MT740750	[33]*
<i>Fusarium aquaticum</i>	LC7502 ^T	NR 182844	[31]
<i>Fusarium aquaticum</i>	LC7502	MW016408	[31]
<i>Fusarium panlongense</i>	LC13656 ^T	NR 182847	[31]
<i>Fusarium panlongense</i>	LC13656	MW016470	[31]

^T Type specimens. * The species *Fusarium nygamai* (CBS 749.97) with the accession number - MT740750, was not yet published. www.ncbi.nlm.nih.gov/nucleotide/2100342893.

Induction of fusaric acid in *Fusarium* sp. (UST-UVG10)

transferred to Erlenmeyer flasks containing each medium. Cultivation was performed at room temperature, under static conditions, and in ambient light. Cultures on liquid media were incubated for 2–3 weeks, depending on the fungal growth. The glucose and pH levels were monitored daily using a glucose strip test and pH strip test, respectively. Fermentation was stopped when the glucose was depleted, and the pH value reached at 7.

Gravity filtration was used to separate the mycelia and supernatant of each culture flask. The mycelia were then soaked in acetone under ultrasonic conditions. The combined organic extracts were evaporated to dryness using a rotary evaporator (40 °C), distilled water was added to the crude product, and extracted again with the same volume of ethyl acetate (EtOAc). The aqueous layer was discarded, while the organic layer was treated with anhydrous sodium sulfate (Na_2SO_4) and evaporated using a rotary evaporator to obtain the crude EtOAc extract from the mycelia. In contrast, the supernatant (or broth) was treated three times with equal volumes of EtOAc. The combined EtOAc extracts from the broth were treated with anhydrous Na_2SO_4 and evaporated using a rotary evaporator to obtain crude EtOAc extracts. There were six crude EtOAc extracts from the three liquid media for this fungal strain.

Antimicrobial activity screening

Kirby-Bauer method was followed for disk diffusion assay. *In vitro* antimicrobial activity was screened using MHA (Mueller Hinton Agar). The plates were prepared by pouring 15 mL of molten media into sterile petri plates. The plates were allowed to solidify for 5 min. After which 0.1% v/v *Staphylococcus aureus* suspension was swabbed and allowed to dry for 5 min. The discs loaded with 1 mg/mL of fungal extract were placed on the surface of the medium, and the plates were incubated at 37 °C for 24 h. Sterile distilled water was used as a negative control, and methanol was used as a solvent control. Streptomycin was used as a positive control. At the end of incubation, inhibition zones formed around the discs were measured with a vernier caliper. These were performed in triplicates.

Minimum inhibitory concentration (MIC) determination

Minimum inhibitory concentration (MIC) as previously described with slight modification^[34]. Plates were prepared aseptically, and the sterile 96-well plate was labeled. A volume of 100 μL of 0.1 mg/mL of test material in 10% (v/v) DMSO was pipetted into the first row of the plate. All other wells contained 50 μL of nutrient broth. Two-fold serial dilutions were performed using a micropipette, and tips were discarded after use so that each well had 50 μL of the test material in serially descending concentrations. Next, 10 μL of resazurin indicator solution was added to each well. Finally, 10 μL of *Staphylococcus aureus* suspension (1.5×10^8 cfu/mL) was added to each well. A total of eight test concentrations were used which ranged from 1.3 to 166 ppm. Each plate was wrapped loosely in cling wrap to prevent bacteria from becoming dehydrated. Further, the plates had a set of controls, including a column with streptomycin as a positive control, a column with all solutions except the test compound, and a column with all solutions except the bacterial solution, which was replaced with 10 μL of nutrient broth. The plates were prepared in triplicate and placed in an incubator at 37 °C for 18–24 h. The color change was then evaluated visually. Any color changes from purple to

pink or colorless were recorded as inhibited growth. The MIC value was determined as the lowest concentration at which color change occurred. Finally, MIC for the test material and the bacterial strain was calculated as the average of three values.

Microplate Alamar Blue Assay (MABA)

The antitubercular activity of the most potent compound against *Mycobacterium tuberculosis* H₃₇Rv (American Type Culture Collection, Rockville, MD, USA) was evaluated using Microplate Alamar Blue Assay (MABA) and Low-Oxygen Recovery Assay (LORA). The test concentrations used ranged from 0.5 to 64 $\mu\text{g/mL}$. MIC₉₀ was determined as the lowest concentration inhibiting fluorescence by 90% compared to the untreated bacterial control. As positive controls, the standard antituberculosis drugs isoniazid, streptomycin, and rifampin were used.

Metabolomic profiling of fungal crude extracts

Samples were prepared in methanol (100 $\mu\text{g/mL}$) and analyzed in triplicate using a Thermo Fisher Q ExactiveTM Plus mass spectrometer (Thermo Fisher Scientific, Waltham, MA) outfitted with an electrospray ionization (ESI) source and a Waters Acquity ultra-performance liquid chromatography (Waters Corporation, Milford, MA). Each sample was injected and eluted in a 3 L volume using a reversed-phase column (BEH C18, 1.7 μm , 2.1 mm \times 50 mm, Waters Corporation) using a binary solvent system consisting of water with 0.1% formic acid (solvent A) and acetonitrile with 0.1% formic acid (solvent B). 10-minute gradient elution began with 10% solvent B for 0.5 min, climbed to 100% B for 8 min, and then returned to starting conditions in the final 1.5 min. Analysis was carried out throughout full scan acquisition, gathering profile data while alternating between positive and negative polarity. The scan range was 120 to 1,500 m/z , and the scan time was 200 ms. The AGC target was set at 1,106, with a capillary voltage and temperature of -0.7 V and 310 °C, respectively; the S-lens RF level was set to 80.00, the spray voltage was 3.7 kV, and the sheath and auxiliary gas flows were 50.15 and 15.16, respectively.

MSConvert tool of MZMine was used to convert RAW data to mzXML format. The dataset was uploaded on GNPS and SIRIUS, which enabled the comparison of sample data to public spectral libraries of reference natural product compounds. Parameters for library matching include precursor ion mass tolerance of 0.01 Da, fragment ion mass tolerance of 0.05 Da, and minimum similarity (cosine) score of 0.70.

The parameters for SIRIUS tools were set as follows: molecular formula candidates retained; molecular formula database, (Bio Database, COCONUT, GNPS & Natural Product); maximum precursor ion m/z computer (10); profile, orbitrap; m/z maximum deviation; ions annotated with MZmine were prioritized and other ions considered (that is $[\text{M}]^+$, $[\text{M}+\text{H}]^+$, $[\text{M}+\text{K}]^+$, $[\text{M}+\text{Na}]^+$, $[\text{M}+\text{H}-\text{H}_2\text{O}]^+$, $[\text{M}+\text{NH}_4]^+$); ZODIAC was not utilized for data mining.

Results

Identification of endophytic fungus and phylogenetic tree construction

Morphological observation revealed isolate UST-UVG10 grown on PDA for 14 days appeared off-white, powdery, semi-submerge scarce to moderate mycelia, entire filamentous margin; reverse pale yellow (Fig. 1). The colony reached a




Fig. 1 *Fusarium* sp. (UST-UVG10) isolated from the leaves of *U. valderramensis*. (a), (b) Observed and reverse view of the colony on PDA plates after 14 d of incubation. (c), (d) Micrographs; macro- and microconidia.

diameter between 40–90 mm in diameter. Macroconidia subhyaline, falcate, (24–46 μm \times 4–6 μm) (\bar{x} = 35.6 \times 5 μm , n = 40). Microconidia subhyaline, ellipsoid to falcate, 0–1 septum (14–21 \times 3–5 μm) (\bar{x} = 17.6 \times 4 μm , n = 40).

For the phylogenetic tree, NCBI blast parameters included sequences from type material and excluded the uncultured samples. Based on our results, it yielded a range of *Fusarium*

species with sequences in this study showing 100%–97% identity and 0.0 e value compared to (UST-UVG10). Evolutionary analyses were conducted in MEGA11. The tree was inferred using ML through the Jukes-Cantor model with Gamma distribution (five categories (+G, parameter = 0.1000)) (Fig. 2). The tree with the highest log likelihood (–1839.24) is shown. The analysis includes 26 nucleotide sequences with a total of 1925 positions in the final dataset. The phylogenetic analysis of ITS sequences identified the isolate to genus level, within the *Fusarium* complex, due to species complexity. Based on the tree, it formed a clade with *F. phyllophilum*, with a minimal branch length. Therefore, UST-UVG10 was given the name *Fusarium* sp. Additional gene markers for full validation are recommended.

Antimicrobial activity screening

Fusarium sp. (UST-UVG10) was subjected to small-scale fermentation in three liquid media namely YM 6.3, Q6 ½, and ZM ½. Preliminary screening of the fungal crude extracts revealed that only the crude extract of *Fusarium* sp. (UST-UVG10) grown in ZM ½ medium showed potent antibacterial activity against *Staphylococcus aureus* (zone of inhibition (ZOI) = 13.85 mm, broth extract; zone of inhibition (ZOI) = 8.11 mm, mycelium extract) (Table 2).

Minimum inhibitory concentration (MIC) vs *Staphylococcus aureus* and *Mycobacterium tuberculosis* H₃₇Rv

During the test for TB susceptibility using *M. tb* H₃₇Rv as the test pathogen and colorimetric MABA as screening method, extract YM 6.3 showed weak inhibition (MABA MIC = 62 $\mu\text{g}/\text{mL}$) while the rest of the extracts are negative.




Fig. 2 The phylogenetic tree of isolated UST-UVG10, based on ITS region amplification, reveals genus-level identification due to its species complexity. Numbers in the node indicate the bootstrap values.

Table 2. Antibacterial activity of the fungal crude extracts against *Staphylococcus aureus*.

Extract	Zone of inhibition (mm)	
YM 6.3	Culture media	6.56
	Mycelia	6
Q6 ½	Culture media	6
	Mycelia	6
ZM ½	Culture media	13.85
	Mycelia	8.11
Streptomycin		31.84

Metabolomic profiling of fungal crude extracts

The constituents present in the fungal crude extracts were profiled using LC-HRESIMS and dereplicated using SIRIUS and GNPS (Fig. 3) to determine the putative metabolites present in the active extracts. In extracts YM6.3 and Q6 ½, the most abundant antibiotic compound is the depsipeptide mycotoxin, beauvericin (2) while pronounced in ZM ½ is the polyketide-derived picolinic acid, fusaric acid (1). Compound 1 is found in minor amounts in the YM 6.3 extract (Fig. 4).



The major antibiotic compound 1 from the ZM ½ extract was purified by repeated preparative HPLC, identified spectroscopically, and screened for its inhibitory activity against *S. aureus* and *M. tuberculosis* H₃₇Rv. Thus, fusaric acid exhibited potent inhibition against *S. aureus* (MIC = 1.30 µg/mL) and is comparable with the MIC of the positive drug antibiotic streptomycin. However, against *M. tuberculosis* H₃₇Rv it showed antimycobacterial activity (MABA MIC = 52.4 µg/mL) (Table 3).

Fusaric acid, 1: white solid; UV (MeOH) max 225, 269 nm.¹H NMR (MeOH-*d*₄, 600 MHz): 0.93 (3H, m, H-10), 1.36 (2H, m, H-9), 1.63 (2H, m, H-8), 2.73 (2H, t, *J* = 7.7 Hz, H-7), 7.89 (1H, d, *J* = 7.9 Hz, H-4), 8.09 (1H, d, *J* = 8.0 Hz, H-3), 8.49 (1H, s, H-6).¹³C NMR (MeOH-*d*₄, 150 MHz): 12.8 (CH₃, C-10), 21.9 (CH₂, C-9), 32.1 (CH₂, C-7), 32.8 (CH₂, C-8), 124.8 (CH, C-3), 138.5 (CH, C-4), 143.0 (C, C-5), 145.5 (C, C-2), 149.7 (CH, C-6), 166.8 (C, C-11); HRESIMS *m/z* 180.1014 [M + H]⁺ (calcd for C₁₀H₁₄NO₂, 180.1019).

Discussion

The importance of selecting plants growing in certain locations as they often harbor secondary metabolites exhibiting diverse biological activities cannot be overemphasized^[35]. This provides a unique breeding ground for microorganisms such as endophytic fungi found inside plant tissues. The host plant *U. valderramensis* is known to harbor and produce bioactive secondary metabolites^[36–40]. This has prompted studies related to its associated endophytic fungi. The isolated endophytic fungus, *Fusarium* sp. (UST-UVG10) was chosen due to its frequent occurrence in the leaves of *U. valderramensis*. It was identified through morphological and molecular analysis and fermented in three different culture media resulting to extracts analyzed for metabolic components and assessed for antibacterial/antimycobacterial activity.

The induction of antimicrobial compounds using the one strain many compounds (OSMAC) approach is an efficient strategy for producing new secondary metabolites, and enhancing production of a specific metabolite^[41]. This method alters

**Fig. 3** LC-HRESIMS chromatograms of the EtOAc extracts of *Fusarium* sp. (UST-UVG10). (a) ZM ½, (b) YM 6.3, (c) Q6 ½.**Fig. 4** Structures of the major antibiotic compounds fusaric acid (1) and beauvericin (2) identified from *Fusarium* sp. (UST-UVG10) extracts.**Table 3.** Minimum Inhibitory Concentrations (MICs) of the fungal extracts against *Staphylococcus aureus* and *Mycobacterium tuberculosis* H₃₇Rv.

Extract/Compound	MIC vs <i>S. aureus</i> (µg/mL)	MABA MIC vs <i>M. tb</i> H ₃₇ Rv (µg/mL)
YM 6.3	–	62
Q6 ½	–	>64
ZM ½	–	>64
Fusaric acid (1)	1.30	52.4
Streptomycin	1.30	–
Isoniazid	–	0.25
Rifampin	–	0.12

fungal culture conditions and induces silent biogenetic clusters to produce different fungal natural products^[42]. Secondary metabolites are produced at specific conditions, wherein their biosynthesis is diversely regulated^[43]. The varying macro- and micronutrient components of the culture medium influence the production of microbial metabolites. Limiting a single nutrient's availability affects the gene clusters involved in controlling S.M.s^[44]. Mainly, carbon and nitrogen sources in the medium affect microbial secondary metabolism, including the C/N ratio also having a role in fermentation products^[45–47]. Thus, metabolomic profiling on YM 6.3, Q6 ½, and ZM ½ using LC-HRESIMS experiments followed by analysis with GNPS and SIRIUS to determine putative secondary metabolites, revealed two major peaks identified as the known antibiotic compounds, fusaric acid (**1**) and beauvericin (**2**). Fusaric acid (**1**) is the abundant and major compound present in the ZM ½ medium with a peak area of 9.03×10^7 , whereas on the other hand, beauvericin (**2**) was the major peak detected in the YM 6.3 and Q6 ½ extracts with a peak area of 1.40×10^7 and 9.28×10^6 , respectively. Interestingly, fusaric acid (**1**) was not observed in the Q6 ½ LC chromatogram. Based on the inhibition data against *S. aureus*, extracts containing high amounts of **1** potentially displayed antibacterial and antimycobacterial activity compared to the extracts that contain **2** as the principal peak component. This was supported by the MIC value of **1** (MIC = 1.30 µg/mL). Based on the peak area and intensity of the base peak of the three chromatograms, the presence of both fusaric acid (**1**) and beauvericin (**2**) led to significant antibacterial activity illustrating synergistic activity. The present study also reports the inhibitory activity of **1** against the virulent TB strain, *M. tuberculosis* H₃₇Rv.

The ZM ½ medium is mainly composed of different types of sugars as carbon sources and uses ammonium sulfate as a nitrogen source. Comparing the varying components of each growth medium, ZM ½ is the only medium that contains a nitrogen source and a relatively high amount of sugar compared to YM 6.3 and Q6 ½. Amino nitrogen and high concentrations of sugar increase the yield of antibacterial compounds produced by *Fusarium* species^[48]. Thus, we noted that ZM ½ medium was able to induce the production of the antimicrobial compound, fusaric acid (**1**) compared to other culture media based on the analysis of the LC-HRESIMS data. The use of complex carbon sources may also affect antibiotic production in microorganisms, having starch as one of the enhancer of carbon source^[49]. Building blocks of starch such as glucose, a regulator for catabolite repression, enables and disables specific pathways including secondary metabolite production that heavily depends on the level of glucose present^[50].

Fusaric acid (FA) and its derivatives exhibit antibacterial effects and are labeled as a non-specific toxin that has antibiotic effects on microorganisms^[51–53]. It is a picolinic acid derivative and is known to be produced by several *Fusarium* species, for example *F. oxysporum*, *F. fujikoro*i, *F. proliferatum*, and *F. verticillioides*^[54–58]. The proposed biosynthetic route for fusaric acid requires aspartate or oxaloacetate and three acetate units, cascading to the production of primary metabolites *L*-aspartic acid paired with malonyl-CoA derived from acetyl-CoA, which is consequently biocatalyzed by an enzyme complex to form

fusaric acid^[59]. To produce the secondary metabolite fusaric acid, the fungus must be cultured in an environment with a rich nitrogen source and sugar. This condition fuels glycolysis and tricarboxylic acid pathway and their respective precursors for the continuous synthesis of fusaric acid. Hence, using ZM ½ aides fusaric acid production. On the other hand, beauvericin (BEA) is a cyclic hexadepsipeptide mycotoxin produced by different *Fusarium* species specifically *F. oxysporum*, *F. subglutinans*, *F. sacchari*, and *F. tardicrescens*^[60–62]. Biosynthesis of beauvericin is executed through rapid catalysis by nonribosomal peptide synthetases (NRPSs), beauvericin synthetase, much like any non-ribosomal peptides (NRPs). The metabolites required are *L*-phenylalanine, *D*-hydroxyisovaleric acid, ATP/Mg²⁺, and S-adenosyl-methionine (AdoMet)^[63,64]. Non-ribosomal peptides are structurally diverse antibiotics developed and produced for a wide range of pharmacological uses^[65]. The concentration of BEA in the three medium extracts is comparable due to probable substrate requirement for NRPS - from fatty acids, alpha-hydroxy acids, and alpha-keto acids, to heterocycles, which are mainly produced if a stable carbon source is present^[66]. Beauvericin also has strong antibacterial activity against various gram-positive and gram-negative pathogenic bacteria including *M. tuberculosis*^[64].

Conclusions

In the present study, the endophytic fungus *Fusarium* sp. (UST-UVG10) associated with *Uvaria valderramensis* was subjected to the OSMAC approach. Metabolomic profiling through LC-HRESIMS followed by dereplication revealed that the antibiotic fusaric acid is highly abundant in the extract obtained from the ZM ½ medium, while the depsipeptide beauvericin remains present in YM6.3 and Q6 ½. Thus, the ZM ½ extract exhibited potent antibacterial and antitubercular activities. A relationship between culture medium components and relative abundance of the antibiotic compounds fusaric acid and beauvericin was established as a potential platform for targeted metabolite production and antimicrobial activity enhancement.

Author contributions

The authors confirm contribution to the paper as follows: study conception and design: Macabeo APG; data collection: Drapisa HJ, Llamas LC, Abellanosa EA, Vidar W; analysis and interpretation of results: Drapisa HJ, Llamas LC, Abellanosa EA, Vidar W; draft manuscript preparation: Drapisa HJ, Abellanosa EA, Macabeo APG. All authors reviewed the results and approved the final version of the manuscript.

Data availability

The data that support the findings of this study are available in the GenBank repository. The ITS sequences of the fungus were recorded and deposited in GenBank with the accession number OQ873338. These data were derived from the following resources available in the public domain: www.ncbi.nlm.nih.gov/genbank.

Copies of NMR and HRMS spectroscopic data of the compounds are available on request from the corresponding author (APGM).

Acknowledgments

Funds and large equipment grant from the Alexander von Humboldt Foundation especially through its Digital Cooperation Fellowship (PHL 1163345 GF-P) during the COVID-19 pandemic is greatly acknowledged. This research was partially funded by the DOST Grants-in-Aide-National Research Council of the Philippines (NRCP). Finally, the DOST-ASTHRDP for supporting the graduate study of HJ Drapisa.

Conflict of interest

The authors declare that they have no conflict of interest.

Dates

Received 25 January 2024; Revised 1 May 2024; Accepted 21 May 2024; Published online 18 June 2024

References

- He X, Guo W, Tang Y, Xiong J, Li Y, et al. 2023. Chloroplast-boosted photodynamic therapy for effective drug-resistant bacteria killing and biofilm ablation. *Journal of Photochemistry and Photobiology B: Biology* 238:112622
- Zhao X, Qi G, Feng Y, Du C. 2023. Application of nematicide avermectin enriched antibiotic-resistant bacteria and antibiotic resistance genes in farmland soil. *Environmental Research* 227:115802
- O'Neill J. 2016. *Tackling drug-resistant infections globally: Final report and recommendations*. Report. Wellcome Trust and HM Government. 84 pp. https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
- Li L, Li H, Tian Q, Ge B, Xu X, et al. 2022. Expression and purification of soluble recombinant β -lactamases using *Escherichia coli* as expression host and pET-28a as cloning vector. *Microbial Cell Factories* 21(1):244
- van Keulen G, Dyson PJ. 2014. Production of specialized metabolites by *Streptomyces coelicolor* A3(2). *Advances in Applied Microbiology* 89:217–66
- Wang R, Piggott AM, Chooi YH, Li H. 2023. Discovery, bioactivity and biosynthesis of fungal piperazines. *Natural Product Reports* 40(2):387–411
- Gaudêncio SP, Pereir, F. 2015. Dereplication: Racing to speed up the natural products discovery process. *Natural Product Reports* 32(6):779–810
- Selegato DM, Castro-Gamboa I. 2023. Enhancing chemical and biological diversity by co-cultivation. *Frontiers in Microbiology* 14:1117559
- Boruta T. 2021. A bioprocess perspective on the production of secondary metabolites by *Streptomyces* in submerged co-cultures. *World Journal of Microbiology and Biotechnology* 37(10):171
- Wibowo JT, Bayu A, Aryati WD, Fernandes C, Yanuar A, et al. 2023. Secondary metabolites from marine-derived bacteria with antibiotic and antibiofilm activities against drug-resistant pathogens. *Marine Drugs* 21(1):50
- Shevchenko M, Sukhikh S, Babich O, Noskova S, Ivanova S, et al. 2021. First insight into the diversity and antibacterial potential of psychrophilic and psychrotrophic microbial communities of abandoned Amber Quarry. *Microorganisms* 9(7):1521
- Baranova AA, Alferova VA, Korshun VA, Tyurin AP. 2020. Antibiotics from extremophilic micromycetes. *Russian Journal of Bioorganic Chemistry* 46:903–71
- Zada S, Sajjad W, Rafiq M, Ali S, Hu Z, et al. 2022. Cave microbes as a potential source of drugs development in the modern era. *Microbial Ecology* 84(3):676–87
- Martinez-Klimova E, Rodríguez-Peña K, Sánchez S. 2017. Endophytes as sources of antibiotics. *Biochemical Pharmacology* 134:1–17
- Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, et al. 2016. Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking. *Nature Biotechnology* 34(8):828–37
- Gao Y, Stuhldreier F, Schmitt L, Wesselborg S, Guo Z, et al. 2020. Induction of new lactam derivatives from the endophytic fungus *Aplosporella javeedii* through an OSMAC approach. *Frontiers in Microbiology* 11:600983
- Abdelmohsen UR, Cheng C, Viegmann C, Zhang T, Grkovic T, et al. 2014. Dereplication strategies for targeted isolation of new antitrypanosomal actinosporins A and B from a marine sponge associated-*Actinokineospira* sp. EG49. *Marine Drugs* 12(3):1220–44
- Akone SH, Mándi A, Kurtán T, Hartmann R, Lin W, et al. 2016. Inducing secondary metabolite production by the endophytic fungus *Chaetomium* sp. through fungal–bacterial co-culture and epigenetic modification. *Tetrahedron* 72(41):6340–47
- Ola ARB, Thomy D, Lai D, Brötz-Oesterhelt H, Proksch P. 2013. Inducing secondary metabolite production by the endophytic fungus *Fusarium tricinctum* through coculture with *Bacillus subtilis*. *Journal of natural products* 76(11):2094–99
- Pinedo-Rivilla C, Aleu J, Durán-Patrón R. 2022. Cryptic Metabolites from marine-derived microorganisms using OSMAC and epigenetic approaches. *Marine Drugs* 20(2):84
- Petrini O. 1991. Fungal endophytes of tree leaves. In *Microbial ecology of the leaves*, eds. Andrews J, Hirano SS. New York: Springer. pp. 179–97. https://doi.org/10.1007/978-1-4612-3168-4_9
- Schulz B, Wanke U, Draeger S, Aust HJ. 1993. Endophytes from herbaceous plants and shrubs: Effectiveness of surface sterilization methods. *Mycological research*, 97(12):1447–50
- White TJ, Bruns T, Lee S, Taylor J. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. *PCR protocols: A Guide to Methods and Applications* 18(1):315–22
- The C. elegans Sequencing Consortium. 1998. Genome sequence of the nematode *C. elegans*: A platform for investigating biology. *Science* 282:2012–18
- O'Donnell K, Cigelnik E. 1997. Two divergent intragenomic rDNA ITS2 types within a monophyletic lineage of the fungus *Fusarium* are nonorthologous. *Molecular Phylogenetics and Evolution* 7(1):103–16
- Vu D, Groenewald M, de Vries M, Gehrman T, Stielow B, et al. 2019. Large-scale generation and analysis of filamentous fungal DNA barcodes boosts coverage for kingdom fungi and reveals thresholds for fungal species and higher taxon delimitation. *Studies in Mycology* 92(1):135–54
- Schoch CL, Robbertse B, Robert V, Vu D, Cardinali G, et al. 2014. Finding needles in haystacks: linking scientific names, reference specimens and molecular data for fungi. *Database* 2014:bau061
- Gargouri S, Balmas V, Burgess L, Paulitz T, Laraba I, et al. 2020. An endophyte of *Macrochloa tenacissima* (esparto or needle grass) from Tunisia is a novel species in the *Fusarium redolens* species complex. *Mycologia* 112(4):792–807
- Watanabe M, Goto K, Sugita-Konishi Y, Kamata Y, Hara-Kudo Y. 2012. Sensitive detection of whole-genome differentiation among closely-related species of the genus *Fusarium* using DNA-DNA hybridization and a microplate technique. *Journal of Veterinary Medical Science* 74(10):1333–1336
- Crous PW, Lombard L, Sandoval-Denis M, Seifert KA, Schroers HJ, et al. 2021. *Fusarium*: More than a node or a foot-shaped basal cell. *Studies in Mycology* 98:100116
- Wang MM, Crous PW, Sandoval-Denis M, Han SL, Liu F, et al. 2022. *Fusarium* and allied genera from China: Species diversity and distribution. *Persoonia - Molecular Phylogeny and Evolution of Fungi* 48:1–53
- O'Donnell K, Nirenberg HI, Aoki T, Cigelnik E. 2000. A multigenic phylogeny of the *Gibberella fujikuroi* species complex: detection of

- additional phylogenetically distinct species. *Mycoscience* 41(1):61–78
33. Riaz M, Khan SN. 2021. *Fusarium nygamai* strain CBS 749.97 internal transcribed spacer 1, partial sequence; 5.8S ribosomal RNA gene and internal transcribed spacer 2, complete sequence; and large subunit ribosomal RNA gene, partial sequence.
34. Sarker SD, Nahar L, Kumarasamy Y. 2007. Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the *in vitro* antibacterial screening of phytochemicals. *Methods* 42(4):321–24
35. Tiwari P, Bae H. 2020. Horizontal gene transfer and endophytes: An implication for the acquisition of novel traits. *Plants* 9(3):305
36. Cabuang PGD, Exconde BS, Salas SR, Macabeo A, Lemana BOC, et al. 2012. Morphological and molecular identification of a novel species of *Uvaria* (Annonaceae) with potential medicinal properties. *Philippine Journal of Systematic Biology* 6:1–16
37. Macabeo APG, Martinez FPA, Kurtán T, Tóth L, Mándi A, et al. 2014. Tetrahydroxanthene-1,3(2H)-dione derivatives from *Uvaria valderriensis*. *Journal of Natural Products* 77(12):2711–15
38. Macabeo APG, Villaflores OB, Franzblau SG, Aguinaldo MAM. 2016. Natural products-based discovery of antitubercular agents from Philippine medicinal plants – A review. *Acta Manilana*, 64:87–98
39. Macabeo APG, Rubio PYM, Higuchi T, Umezawa N, Faderl C, et al. 2017. Polyoxygenated seco-cyclohexenes and other constituents from *Uvaria valderriensis*. *Biochemical Systematics and Ecology* 71:200–4
40. Christopher R. 2022. Plant species of the genus *Uvaria*: Ethnobotanical uses, biological activities and phytochemistry. *Natural Product Research* 36(11):2946–61
41. Hewage RT, Aree T, Mahidol C, Ruchirawat S, Kittakoop P. 2014. One strain-many compounds (OSMAC) method for production of polyketides, azaphilones, and an isochromanone using the endophytic fungus *Dothideomycete* sp. *Phytochemistry* 108:87–94
42. Hemphill CFP, Sureechatchaiyan P, Kassack MU, Orfali RS, Lin W, et al. 2017. OSMAC approach leads to new fusarielin metabolites from *Fusarium tricinctum*. *Journal of Antibiotics* 70(6):726–32
43. Tudzynski B. 2014. Nitrogen regulation of fungal secondary metabolism in fungi. *Frontiers in Microbiology* 5:656
44. Brakhage AA. 2013. Regulation of fungal secondary metabolism. *Nature Reviews. Microbiology* 11(1):21–32
45. Singh V, Haque S, Niwas R, Srivastava A, Pasupuleti M, et al. 2017. Strategies for fermentation medium optimization: An in-depth review. *Frontiers in Microbiology* 7:2087–102
46. Abd Rahim MH, Lim EJ, Hasan H, Abbas A. 2019. The investigation of media components for optimal metabolite production of *Aspergillus terreus* ATCC 20542. *Journal of Microbiological Methods* 164:105672
47. Brzonkalik K, Hümmer D, Sylđatk C, Neumann A. 2012. Influence of pH and carbon to nitrogen ratio on mycotoxin production by *Alternaria alternata* in submerged cultivation. *AMB Express* 2:28
48. El-Mahdy OM, Mohamed HI, El-Ansary AE. 2023. Optimizations of exopolysaccharide production by *Fusarium nygamai* strain AJTYC1 and its potential applications as an antioxidant, antimicrobial, anti-cancer, and emulsifier. *BMC Microbiology* 23:345
49. Selvaraj JN, Ganapathi U, Vincent SGP, Ramamoorthy S, Thavasimuthu C. 2023. Statistical optimization of media components for antibiotic production in *Streptomyces* sp. CMSTAAHAL-3. *Electronic Journal of Biotechnology* 65:1–13
50. Lengeler J. 2013. *Catabolite repression*. In *Elsevier eBooks* pp. 447–452. Elsevier.
51. Wang B, Song CR, Zhang QY, Wei PW, Wang X, et al. 2022. The fusaric acid derivative qy17 inhibits *Staphylococcus haemolyticus* by disrupting biofilm formation and the stress response via altered gene expression. *Frontiers in Microbiology* 13:822148
52. Crutcher FK, Puckhaber LS, Stipanovic RD, Bell AA, Nichols RL, et al. 2017. Microbial resistance mechanisms to the antibiotic and phytotoxin fusaric acid. *Journal of Chemical Ecology* 43:996–1006
53. Huang BB, Liu YY, Zhu PF, Jiang YC, Ouyang MA. 2020. Concise total synthesis and antifungal activities of fusaric acid, a natural product. *Molecules* 25(17):3859
54. Staropoli A, Guastaferrero VM, Vinale F, Turrà D, Di Costanzo L, et al. 2024. Repression of autocrine pheromone signaling leads to fusaric acid over-production. *Natural Product Research* 38:1967–71
55. Arumugam T, Ghazi T, Abdul NS, Chuturgoon AA. 2021. A review on the oxidative effects of the fusariotoxins: fumonisin B1 and fusaric acid. In *Toxicology*, eds. Patel VB, Preedy VR. Cambridge, MA: Elsevier. pp. 181–90. <https://doi.org/10.1016/b978-0-12-819092-0.00019-4>
56. Niehaus EM, von Bargaen KW, Espino JJ, Pfannmüller A, Humpf HU, et al. 2014. Characterization of the fusaric acid gene cluster in *Fusarium fujikuroi*. *Applied Microbiology and Biotechnology*, 98:1749–62
57. Munkvold GP, Arias S, Taschl I, Gruber-Dorninger C. 2019. Mycotoxins in corn: Occurrence, impacts, and management. In *Corn*, ed. Serna-Saldivar SO. Oxford: AACC International Press. 3rd Edition. pp. 235–87. <https://doi.org/10.1016/b978-0-12-811971-6.00009-7>
58. Merel D, Savoie JM, Mata G, Salmones D, Ortega C, et al. 2020. Methanolic extracts from cultivated mushrooms affect the production of Fumonisin B and Fusaric acid by *Fusarium verticillioides*. *Toxins* 12(6):366
59. Hai Y, Chen M, Huang A, Tang Y. 2020. Biosynthesis of mycotoxin fusaric acid and application of a PLP-Dependent enzyme for chemoenzymatic synthesis of substituted L-pipecolic acids. *Journal of the American Chemical Society* 142(46):19668–77
60. Rana S, Singh SK, Dufossé L. 2022. Multigene phylogeny, beauvericin production and bioactive potential of *Fusarium* strains isolated in India. *Journal of Fungi* 8(7):662
61. Mohammed A, Al-Ani LKT. 2021. Identification and production of beauvericin by *Fusarium subglutinans* and *F. sacchari* from sugarcane. *Brazilian Archives of Biology and Technology* 64:e21200088
62. Vásquez-Bonilla JN, Barranco-Florido JE, Ponce-Alquicira E, Rincón-Guevara MA, Loera O. 2022. Improvement of beauvericin production by *Fusarium oxysporum* AB2 under solid-state fermentation using an optimized liquid medium and co-cultures. *Mycotoxin Research* 38(3):175–83
63. Wang Q, Xu L. 2012. Beauvericin, a bioactive compound produced by fungi: A short review. *Molecules* 17(3):2367–77
64. Wu Q, Patocka J, Nepovimova E, Kuca K. 2018. A review on the synthesis and bioactivity aspects of beauvericin, a *Fusarium* mycotoxin. *Frontiers in Pharmacology* 9:1338–49
65. Agrawal S, Adholeya A, Deshmukh SK. 2016. The pharmacological potential of non-ribosomal peptides from marine sponge and tunicates. *Frontiers in Pharmacology* 7:333–53
66. Iacovelli R, Bovenberg RAL, Driessen AJM. 2021. Nonribosomal peptide synthetases and their biotechnological potential in *Penicillium rubens*. *Journal of Industrial Microbiology & Biotechnology* 48(7–8):kuab045



Copyright: © 2024 by the author(s). Published by Maximum Academic Press, Fayetteville, GA. This article is an open access article distributed under Creative Commons Attribution License (CC BY 4.0), visit <https://creativecommons.org/licenses/by/4.0/>.